SCHEMBL6775871

SCHEMBL6775871

CCCCCc1cc(O)c2c3c(C(N)=O)cccc3n(Cc3cccc(F)c3)c2c1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
GLA P06280 1/20 0.40
CNR2 P34972 2/20 0.39
PPARG P37231 3/20 0.39
F10 P00742 1/20 0.37
PLA2G2A P14555 2/20 0.36
TSPO P30536 1/20 0.36
PPARA Q07869 1/20 0.35
POLB P06746 1/20 0.35
IDO1 P14902 1/20 0.35
DRD2 P14416 1/20 0.35
HTR6 P50406 1/20 0.35
MAPK8 P45983 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5212214 0.90 PPARG (0.46) PPARGPLA2G2APPARA
SCHEMBL6770304 0.90 CNR1 (0.42) CNR2PPARGF10PLA2G2APPARA
SCHEMBL6774816 0.89 LMNA (0.43) LMNAGLAF10PLA2G2ATSPO
SCHEMBL6889327 0.89 MAPT (0.41) LMNAGLACNR2F10POLB
SCHEMBL6774931 0.89 PLA2G2A (0.48) CNR2PPARGPLA2G2A
SCHEMBL6773827 0.89 PPARG (0.39) PPARGF10PLA2G2APPARAPOLB
SCHEMBL6781743 0.88 TRPV1 (0.45) LMNAPPARGF10POLBMAPK8
SCHEMBL6781319 0.88 PPARG (0.42) CNR2PPARGF10PLA2G2APPARA
SCHEMBL6776320 0.88 PPARG (0.41) CNR2PPARGPLA2G2APPARA
SCHEMBL6776550 0.86 ADRA1D (0.41) PPARGPLA2G2APPARAPOLBMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed